Back to Search
Start Over
Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity
- Source :
- Nature Communications, Vol 10, Iss 1, Pp 1-11 (2019)
- Publication Year :
- 2019
- Publisher :
- Nature Portfolio, 2019.
-
Abstract
- Agonistic 4-1BB antibodies developed for cancer immunotherapy have suffered from either hepatotoxicity or insufficient anti-cancer activity. Here the authors determine the contribution of FcγR binding and agonistic strength to these outcomes, and engineer a 4-1BB antibody with potent anti-tumor effect and no liver toxicity in mice.
- Subjects :
- Science
Subjects
Details
- Language :
- English
- ISSN :
- 20411723
- Volume :
- 10
- Issue :
- 1
- Database :
- Directory of Open Access Journals
- Journal :
- Nature Communications
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.00f1cb7bc64c4223a182e521b81631ef
- Document Type :
- article
- Full Text :
- https://doi.org/10.1038/s41467-019-10088-1